Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Elixir Department: SOP for Handling of Intermediate Product – V 2.0

Posted on By

Elixir Department: SOP for Handling of Intermediate Product – V 2.0

Standard Operating Procedure for Handling of Intermediate Product During Elixir Manufacturing

Department Elixir Department
SOP No. SOP/ELX/085/2025
Supersedes SOP/ELX/085/2022
Page No. Page 1 of 8
Issue Date 11/04/2025
Effective Date 15/04/2025
Review Date 11/04/2026

1. Purpose

To establish a standardized procedure for handling intermediate product during various stages of elixir manufacturing to prevent contamination, maintain product integrity, and ensure traceability.

2. Scope

This SOP is applicable to all intermediate bulk products generated during the manufacturing process of elixirs in the Elixir Department before the final product stage.

3. Responsibilities

  • Production Operator:
    • Label, cover, transfer, and store intermediate products appropriately.
  • Production Supervisor:
    • Ensure intermediate products are handled according to predefined holding conditions.
    • Verify documentation and time tracking.
  • QA Officer:
    • Review holding records, verify product status, and authorize further processing.
See also  Elixir Department: SOP for Recording Parameters in BMR - V 2.0

4. Accountability

The Head of Production is accountable for ensuring that all intermediate products are handled as per this SOP and that no mix-up, contamination, or deterioration occurs.

5. Procedure

5.1 Identification and Labeling

  1. Immediately after completion of a processing
step (e.g., mixing, pH adjustment), label the intermediate product with a “INTERMEDIATE PRODUCT” tag (Annexure-1).
  • The label must include:
    • Product Name
    • Batch Number
    • Stage (e.g., Post-Mixing)
    • Date and Time
    • Operator Initials
  • 5.2 Handling and Storage

    1. Transfer the intermediate product to designated storage or holding tanks using sanitized transfer lines.
    2. Cover tanks securely and maintain nitrogen blanketing if required for volatile products.
    3. Maintain holding conditions such as:
      • Temperature: as per product specification
      • Duration: not to exceed approved hold time (typically ≤48 hours)

    5.3 Documentation and Time Tracking

    1. Record start and end time of holding in the Intermediate Holding Log (Annexure-2).
    2. Any deviation in holding time must be reported immediately and evaluated for product impact.

    5.4 Release for Next Step

    1. QA shall perform visual inspection and review holding time and conditions.
    2. Once verified, QA will sign off the Intermediate Holding Log for batch release to the next manufacturing stage (e.g., filtration, flavor addition).

    5.5 Precautions

    1. Do not mix intermediate batches unless approved by QA.
    2. Protect intermediate product from direct light, dust, and personnel traffic.
    3. Never use unclean or unvalidated equipment for holding or transfer.

    6. Abbreviations

    • SOP: Standard Operating Procedure
    • QA: Quality Assurance
    • BMR: Batch Manufacturing Record

    7. Documents

    1. Intermediate Product Tag (Annexure-1)
    2. Intermediate Holding Log (Annexure-2)
    3. Batch Manufacturing Record (BMR)

    8. References

    • 21 CFR Part 211.111 – Time Limitations on Production
    • WHO TRS 1010 – GMP for Pharmaceutical Products

    9. SOP Version

    Version: 2.0

    10. Approval Section

    Prepared By Checked By Approved By
    Signature
    Date
    Name
    Designation
    Department

    11. Annexures

    Annexure-1: Intermediate Product Tag

    Product Name Batch No. Stage Date Time Operator Status
    Paracetamol Elixir ELX-1024 Post-Mixing 11/04/2025 02:00 PM Rajesh Kumar INTERMEDIATE

    Annexure-2: Intermediate Holding Log

    Date Batch No. Tank ID Start Time End Time Holding Duration QA Release
    11/04/2025 ELX-1024 ST-03 02:00 PM 04:30 PM 2.5 Hours Sunita Reddy

    Revision History:

    Revision Date Revision No. Revision Details Reason for Revision Approved By
    01/01/2024 1.0 Initial SOP Release New SOP QA Head
    11/04/2025 2.0 Enhanced traceability and holding log GMP Audit Recommendation QA Head
    See also  Elixir Department: SOP for Sampling During Elixir Manufacturing - V 2.0
    Elixers V 2.0 Tags:Elixir colorants, Elixir dosage form, Elixir filtration techniques, Elixir flavoring agents, Elixir formulation, Elixir GMP compliance, Elixir manufacturing process, Elixir manufacturing SOPs, Elixir packaging requirements, Elixir pharmacopoeial standards, Elixir preparation methods, Elixir preservatives, Elixir production equipment, Elixir quality control, Elixir regulatory guidelines, Elixir shelf life, Elixir stability testing, Elixir sterilization methods, Elixir storage conditions, Elixir sweetening agents, Elixir viscosity modifiers, Hydroalcoholic solutions, Medicated elixirs, Non-medicated elixirs, Pharmaceutical elixirs

    Post navigation

    Previous Post: API Manufacturing: SOP for Review and Approval of Batch Manufacturing Records (BMR) – V 2.0
    Next Post: Biosimilars: SOP for Cross-Contamination Control in Bioreactor Operations – V 2.0

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Gels V 2.0
    • Injectables V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2025 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version